PCSA (Processa Pharmaceuticals) Debt-to-Equity: 0.00 (As of Mar. 2026)

What is Processa Pharmaceuticals Debt-to-Equity?

Processa Pharmaceuticals PCSA +9.64% 28 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates PCSA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 965 Biotechnology companies, Processa Pharmaceuticals ranks better than 99.9% on this metric.

Processa Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. Processa Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. Processa Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $2.54 Mil. Processa Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Processa Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

PCSA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.74 Med: 0.02 Max: 6.57
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Processa Pharmaceuticals was 6.57. The lowest was -0.74. And the median was 0.02.

PCSA's Debt-to-Equity is ranked better than
99.9% of 965 companies
in the Biotechnology industry
Industry Median: 0.16 vs PCSA: 0.01

Processa Pharmaceuticals (NAS:PCSA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Processa Pharmaceuticals Debt-to-Equity Related Terms

Processa Pharmaceuticals Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals Debt-to-Equity Chart

Processa Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Debt-to-Equity

Get a 7-Day Free Trial

0.00

0.03

0.04

0.00

Processa Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.00	0.00	0.00	0.00

PCSA vs ELAB, MBIO, DRMA: Debt-to-Equity Comparison

For the Biotechnology subindustry, Processa Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Processa Pharmaceuticals Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's Debt-to-Equity falls into.

Save Embed

28GF Score

Processa Pharmaceuticals Inc PCSA

Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Processa Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Processa Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	5.577
	=	0.00

Processa Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	2.541
	=	0.00

Frequently Asked Questions Learn more about Debt-to-Equity →

What does a Debt-to-Equity of 0.00 mean?

Processa Pharmaceuticals (PCSA) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Processa Pharmaceuticals and its competitors. According to the industry distribution chart, Processa Pharmaceuticals ranks #1 out of 965 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.

Is Processa Pharmaceuticals' Debt-to-Equity too high?

Processa Pharmaceuticals' current Debt-to-Equity is 0.00. Based on the distribution chart, Processa Pharmaceuticals ranks #1 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Processa Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does Processa Pharmaceuticals' Debt-to-Equity compare to ELAB and MBIO?

According to the Biotechnology industry distribution chart, Processa Pharmaceuticals ranks #1 out of 965 companies for Debt-to-Equity. This places Processa Pharmaceuticals in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-Equity for a Biotechnology company?

The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-Equity mean?

A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Processa Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Processa Pharmaceuticals's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Processa Pharmaceuticals stock overvalued right now?

Processa Pharmaceuticals (PCSA) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Processa Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-Equity calculated?

Debt-to-Equity is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Processa Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ELAB MBIO DRMA LIMN TCRT GNPX MLEC CLGN CPMV ADIL VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960

Website https://www.processapharmaceuticals.com

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

28GF Score

Get the complete analysis for PCSA

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16

Price

View PCSA Analysis

See Debt-to-Equity data for all stocks →